“From the very beginning of the launch of the Russian Sputnik V vaccine, developed by the Gamaleya Research Center for Electrochemistry and Microbiology and registered by the Russian Ministry of Health on August 11, Russia has seen interest and hope from many countries and has already received applications for the purchase of more than one billion doses of the vaccine.
Nevertheless, we also faced criticism and questions from a number of Western countries and companies, ”RIA Novosti quotes Dmitriev.
According to him, registration was carried out according to an accelerated procedure due to the positive results of the first and second phases of clinical trials and the fact that the platform based on human adenoviral vectors has been confirmed as the safest platform in the world during decades of research.
Dmitriev also noted that the vaccine uses the technology of two human adenoviral vectors, which no one else in the world uses to prevent COVID-19.
"Vectors are genetically modified viruses that are incapable of reproduction and carry the genetic material of the outer shell of the coronavirus," he said.
In addition, Dmitriev recalled that data on clinical studies were published on September 4 in The Lancet.
"As a result of phase I-II clinical trials of the Sputnik V vaccine, no serious adverse events were detected," he said.
According to him, in 100% of participants in clinical trials, the vaccine has formed a stable humoral and cellular immune response.
“Clinical trials of Sputnik V in the UAE, Saudi Arabia, the Philippines, India and Brazil will begin this month.
The preliminary results of the Phase III clinical trials of Sputnik V will be published in October - November 2020, ”Dmitriev added.
Earlier, the head of the therapeutic service of the Tyumen Regional Clinical Hospital No. 1 Elena Zhuravleva, in an interview with URA.RU, assessed the possibility of a second wave of COVID-19.